Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Intermittent androgen replacement for intense hypogonadism symptoms in castrated patients

Prostate Cancer and Prostatic Diseases volume 9, pages 39–41 (2006)Cite this article

Abstract

Objectives: For locally advanced prostate cancer management, medical androgen deprivation and surgical castration are alternatives. These hormonal treatments may cause a myriad of side effects, such as osteoporosis with increased risk of fractures, anemia, behavioral changes and lack of sexual interest. We evaluated the feasibility of intermittent androgen replacement in surgically castrated patients with significant side effects.

Methods: Five patients with advanced prostate cancer, ranging from 71 to 77 years of age (mean age=74 years), surgically castrated for at least 3 years, with important symptoms of hypoandrogenism received testosterone replacement. They were followed with PSA and testosterone measurement every other month and bone scans every 6 months.

Results: For the first year all patients improved significantly, none of them showed PSA increase over 10 ng/ml. There was no evidence of local recurrence or distant disease. After 18 months, only one patient (20%) had a significant PSA increase, controlled by androgen withdrawal. No side effects or metastasis were observed.

Conclusions: Hormonal replacement in patients that underwent castration seems to be feasible in improving intense symptoms associated to androgen deprivation. After 18 months, no evidence of recurrence was noted. It is an experimental alternative for highly symptomatic patients, but the short follow-up and the small number of patients cannot allow for definitive conclusions and should be studied further.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Hamdy FC . The molecular mechanisms of hormone resistance in prostate cancer. In: Kurth KH, Mickish GH, Schröder FH (eds). Renal, Bladder, Prostate and Testicular Cancer, An Update. The Parthenon Publishing Group Ltd: Amsterdan, 2000; pp 177–183.

    Google Scholar 

  2. Miyamoto H, Messing EM, Chang C . Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004; 61: 332–353.

    Article  CAS  Google Scholar 

  3. Denis LJ, Griffiths K . Endocrine treatment in prostate cancer. Semin Surg Oncol 2000; 18: 52–74.

    Article  CAS  Google Scholar 

  4. Hedlund PO . Side effects of endocrine treatment and their mechanisms: castration, antiandrogens and estrogens. Prostate Suppl 2000; 10: 32–37.

    Article  CAS  Google Scholar 

  5. Lucas MD, Strijdom SC, Berk M . Quality of life, sexual functioning and sex role identity after surgical orchidectomy in patients with prostatic cancer. Scand J Urol Nephrol 1995; 29: 497–500.

    Article  CAS  Google Scholar 

  6. Holzbeierlein JM, McLaughlin MD, Thrasher JB . Complications of androgen deprivation therapy for prostate cancer. Curr Opin Urol 2004; 14: 177–183.

    Article  Google Scholar 

  7. Melton III LJ, Alothman KI, Khosla S, Achenbach SJ, Oberg AL, Zincke H . Fracture risk following bilateral orchiectomy. J Urol 2003; 169: 1747–1750.

    Article  Google Scholar 

  8. Pether M, Goldenberg SL, Bhagirath K, Gleave M . Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience. Can J Urol 2003; 10: 1809–1814.

    PubMed  Google Scholar 

  9. Agarwal PK, Oefelein MG . Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005; 173: 533–536.

    Article  CAS  Google Scholar 

  10. Patterson SG, Balducci L, Pow-Sang JM . Controversies surrounding androgen deprivation for prostate cancer. Cancer Control 2002; 9: 315–325.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Universidade Estadual de Campinas – UNICAMP, Campinas, Sao Paulo, Brazil

    U Ferreira, V A Leitao, F Denardi, W E Matheus, R M Stopiglia & N R Netto Jr

Authors
  1. U Ferreira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V A Leitao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Denardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W E Matheus
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R M Stopiglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N R Netto Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U Ferreira.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ferreira, U., Leitao, V., Denardi, F. et al. Intermittent androgen replacement for intense hypogonadism symptoms in castrated patients. Prostate Cancer Prostatic Dis 9, 39–41 (2006). https://doi.org/10.1038/sj.pcan.4500833

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500833

Keywords

This article is cited by

Search

Advanced search

Quick links